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Risk factorsNeuroprotective strategies for ischemic stroke have failed to translate from bench to bedside, possibly
due to the lack of consideration of key clinical co-morbidities. Stroke and co-morbidities are associated
with raised levels of the pro-inflammatory cytokine interleukin-1 (IL-1). Inhibition of IL-1 by the admin-
istration of interleukin-1 receptor antagonist (IL-1Ra) has shown to be neuroprotective after experimen-
tal cerebral ischemia. Stroke can also trigger a robust neuroreparative response following injury, yet
many of these new born neurons fail to survive or integrate into pre-existing circuits. Thus, we explore
here effects of IL-1Ra on post-stroke neurogenesis in young and aged/co-morbid rats. Aged lean, aged
Corpulent (a model of atherosclerosis, obesity and insulin resistance) and young Wistar male rats were
exposed to transient cerebral ischemia, received subcutaneous IL-1Ra 3 and 6 h during reperfusion,
and effects on stroke outcome and neurogenesis were analyzed. Our results show that administration
of IL-1Ra improves stroke outcome in both young and aged/co-morbid rats. Furthermore, IL-1Ra not only
increases stem cell proliferation, but also significantly enhances neuroblast migration and the number of
newly born neurons after cerebral ischemia. Overall, our data demonstrate that systemic administration
of IL-1Ra improves outcome and promotes neurogenesis after experimental stroke, further highlighting
the therapeutic potential of this clinically approved drug.
 2016 The Authors. Published by Elsevier Inc. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).1. Introduction
Cerebral ischemia is the second leading cause of death and dis-
ability worldwide with treatment limited to fibrinolysis and
intravascular therapy, both applicable in a low percentage of
patients. Other strategies to improve outcome after stroke have
failed to translate from the preclinical setting to the clinic, and
with these failures have come calls for more rigorous and transpar-
ent approaches to experimental design and conduct (Albers et al.,
2011; Howells et al., 2014). Highlighted in many of these calls is
the need to consider age and co-morbidities experimentally, as
these involve a strong inflammatory response, and are associated
with increased risk of stroke and poor post-stroke outcomes.The pro-inflammatory cytokine interleukin-1 (IL-1) is a major
driver of inflammation, with well documented detrimental effects
in multiple preclinical models of systemic inflammatory disease as
well as in cerebral ischemia (Denes et al., 2010; Fan et al., 2013;
McColl et al., 2007). To this end, the selective, naturally occurring
competitive inhibitor of IL-1, interleukin-1 receptor antagonist
(IL-1Ra) has shown potential as a new treatment for stroke
(Emsley et al., 2005; Banwell et al., 2009; Smith et al., 2012). More
specifically, in a number of experimental stroke paradigms IL-1Ra
reduces infarct volume and improves long term functional out-
come, including in co-morbid animals (McColl et al., 2007; Relton
and Rothwell, 1992; Pradillo et al., 2012; Girard et al., 2014). How-
ever, exact mechanisms by which IL-1Ra is neuroprotective are yet
to be fully established.
While much research has focused on limiting ischemic damage
in the initial stages of acute reperfusion, it is also important to
understand mechanisms that underpin brain repair following
injury and develop strategies that enhance reparative endogenous
processes, including adult neurogenesis. Ischemic injury elicits ats after
2 J.M. Pradillo et al. / Brain, Behavior, and Immunity xxx (2016) xxx–xxxrobust neurogenic response (Arvidsson et al., 2002) by stimulating
production of neuronal progenitor cells (NPCs) in distinct neuro-
genic regions, which include the subventricular zone (SVZ) and
the subgranular zone (SGZ), to generate new functional neurons.
Though mechanisms underlying post-stroke neurogenesis and
the influence of inflammation on these processes are still poorly
understood, it has been observed in young and aged animals that
inflammation impairs both basal levels of neurogenesis and atten-
uates the neurogenic response triggered by CNS injury via induc-
tion of the pro-inflammatory cytokines (Vallieres et al., 2002;
Ben-Hur et al., 2003; Wong et al., 2004; Bachstetter et al., 2011).
IL-1, for example, reduces the proliferation and differentiation of
NPCs to neurons in pathologies such as stress and depression,
effects reversed by administration of IL-1Ra (Koo and Duman,
2008; Zhang et al., 2013).
Here, we explored how inhibition of IL-1 actions by clinically
relevant, delayed administration of subcutaneous IL-1Ra affects
stroke outcome and neurogenesis up to 28 days after experimental
ischemia, in aged/co-morbid and young rats.2. Materials and methods
2.1. Animals
All experiments were performed using 13-month-old male, lean
(JCR:LA-lean (cp/); 400–500 g) and Corpulent (Cp) (JCR:LA-cp (cp/
cp); 900–1000 g) rats (University of Alberta, Edmonton, Canada)
and 2-month-old Wistar rats (200–250 g; Charles River, Wilming-
ton, MA, USA). Cp rats are homozygous for the autosomal recessive
cp gene (cp/cp), and spontaneously develop obesity, hyperlipi-
demia, insulin resistance, glomerular sclerosis, and atherosclerosis
with enhanced vascular contractility and reduced vascular relax-
ation (Mangat et al., 2007). Animals were allowed free access to
food and water and were maintained under temperature, humid-
ity, and light-controlled conditions. All procedures were performed
under appropriate United Kingdom Home Office licenses and
adhered to the Animals (Scientific Procedures) Act (1986)
Kilkenny et al., 2010.2.2. Treatment
Animals were randomized for all experiments and assessments
were performed in a blinded manner. Lean, Cp and young Wistar
rats received two doses (subcutaneous) of placebo or IL-1Ra
(25 mg/kg, 12.5 mg/kg and 50 mg/kg respectively) at 3 and 6 h post
reperfusion and were allocated randomly to the following experi-
mental groups sacrificed on post-stroke day 7: aged lean
+ tMCAO + placebo (n = 10); aged lean + tMCAO + IL-1Ra (n = 10);
aged Cp + tMCAO + placebo (n = 9); aged Cp + tMCAO + IL-1Ra
(n = 9); young Wistar + tMCAo + placebo (n = 8) and young Wis-
tar + tMCAo + IL-1Ra (n = 8). Another two groups of young Wistar
were sacrificed at 14d after stroke: young Wistar + tMCAo
+ placebo-14d (n = 8) and young Wistar + tMCAo + IL-1Ra-14d
(n = 8) to determine neuroblast migration, and two groups at
28d: young Wistar + tMCAo + placebo-28d (n = 8) and young Wis-
tar + tMCAo + IL-1Ra-28d (n = 8) to analyze the number of new
integrated neurons. Group sizes were determined by power calcu-
lation (a = 0.05, b = 0.2).
The pharmacokinetic profile of subcutaneous human IL-1Ra (r-
met-huIL-1Ra: Kineret; Amgen, Thousand Oaks, CA, USA) or pla-
cebo (Amgen, Thousand Oaks, CA, USA) was assessed in young
and aged-comorbid rats as previously described (Greenhalgh
et al., 2010). Owing to the highly lipophobic formulation of the
drugs, obese Cp rats received half the dose of IL-1Ra (50%) per body
weight compared with aged lean rats (Pradillo et al., 2012). PlasmaPlease cite this article in press as: Pradillo, J.M., et al. Reparative effects of inte
cerebral ischemia. Brain Behav. Immun. (2016), http://dx.doi.org/10.1016/j.bbilevels of IL-1Ra (measured by ELISA) in Lean/Cp rats reached a con-
centration of 8000 ng/ml 8 h after both injections. Young Wistar
rats were given double the dose of the aged lean animals due to the
faster metabolism of young animals (Mondon and Starnes, 1992).
Following studies by Greenhalgh et al. (2010), a single administra-
tion of 100 mg/kg of IL-1Ra to young rats at the time of the MCAO,
resulted in a plasma concentration of 9000 ng/ml 8 h after its
administration. Therefore the administration regime of IL-1Ra used
here resulted in comparable plasma levels of drug, at what we
believe to be clinically therapeutic concentrations (Emsley et al.,
2005).
2.3. Focal cerebral ischemia
Focal cerebral ischemia was induced in aged lean and Cp rats by
90min transient occlusion of the left middle cerebral artery
(tMCAO) as described previously (Pradillo et al., 2012). Focal cere-
bral ischemia was induced in young Wistar rats by 70 min tran-
sient occlusion of the left middle cerebral artery and left
common carotid artery (CCA). The slight difference in surgical pro-
tocol was due to a resistance of young rats to infarction when only
the MCA was occluded (data not shown). It was necessary to
occlude both the MCA and CCA in these young healthy animals
to achieve similar infarcts to aged lean/corpulent rats infarcts to
analyze the IL-1Ra effect on neurogenesis, due to the influence of
infarct size in the neurogenic response after stroke (Moraga
et al., 2014). Isoflurane (2% for induction and 1.5% during surgery)
was used in a mixture of 70% N2O and 30% O2. Core body temper-
ature was maintained at 37.0 C ± 0.5 C throughout the surgery by
a heating blanket (Homeothermic Blanket Control Unit; Harvard
Apparatus, Kent, UK). Ischemia was induced by a transient ligature
of the left MCA trunk and/or CCA with a 10–0 suture (Prolene, Ethi-
con, Somerville, NJ, USA). Occlusion and reperfusion were con-
firmed visually under the surgical microscope. After surgery,
animals were returned to home cages and allowed free access to
water and food. Animals were excluded from statistical analysis
based on an a priori exclusion criterion, namely if animals experi-
enced brain hemorrhage, lack of reperfusion or if the surgery took
longer than 45 min and there was excessive bleeding (2 aged leans
were excluded in total). Only one animal died during the duration
of the study due to anesthetic overdose.
2.4. Measurement of infarct volume and BBB damage
Lesion volume and edema were assessed on T2W brain images
obtained at 24 h and 7 d after stroke, using a 7-T, horizontal-bore
magnet (Agilent Technologies, UK) interfaced to a Bruker Avance
III console (Bruker Biospin, UK) using a surface transmit-receive
coil. Images were analyzed using Anatomist software (http://brain-
visa.info). In the group of young Wistar rats sacrificed at 28 d, the
loss of cortex was determined in brain sections by Nissl staining as
described previously (Pradillo et al., 2012).
Blood–brain barrier (BBB) damage was determined by immuno-
histochemical staining of endogenous rat immunoglobulin G (IgG)
as described previously (Greenhalgh et al., 2010) in all the experi-
mental groups at 7d, and in young Wistar rats at 14d of
reperfusion.
2.5. Stroke outcome
Neurological status was assessed blinded to drug treatment,
before and at different time points up to 28d after stroke, and by
the use of motor, behavioral and cylinder tests (Hunter et al.,
2000; Madrigal et al., 2003; Schallert et al., 2000). For the motor
and behavioral scales, each test was conducted three times per trial
and the average taken to determine outcome. For the cylinder test,rleukin-1 receptor antagonist in young and aged/co-morbid rodents after
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4 min. All rears were scored by the use of the right paw, left
paw, or both paws during rearing (Encarnacion et al., 2011). The
different forelimb preference, for placements made, was calculated
as a percentage of the total number of placements made.
2.6. Incorporation of bromodeoxyuridine (BrdU)
To examine the number of new integrated neurons in young
Wistar rats at 28 d after experimental stroke, animals were
injected intraperitoneally with 50 mg/kg bromodeoxyuridine
(BrdU; Sigma; UK) twice a day on days 4, 5 and 6 post-ischemia.
2.7. Tissue processing
Rats were transcardially perfused with 0.9% saline followed by
4% paraformaldehyde (pH = 7.4). Brains were removed, post fixed,
cryoprotected in 30% sucrose and frozen at 20 C. Sections
(30 lm) were cut on a sledge microtome (Bright series 8000;
Bright Instruments, Huntingdon, UK) and stored at 20 C in anti-
freeze solution (30% ethylene glycol and 20% glycerol in
phosphate-buffered saline) until processing.
2.8. Immunofluorescence
With this technique we evaluated different markers of neuroge-
nesis. We first analyzed NPCs proliferation in the SVZ by staining
for Ki67, a nuclear protein associated with cellular proliferation
which is expressed in all phases of the cell cycle, except the resting
phase (Kee et al., 2002). To determine the differentiation of NPCs
into neuroblasts, we stained for Doublecortin (DCX), a microtubule
associated phosphoprotein which is a neuroblast marker (Rao and
Shetty, 2004). Finally, we studied the number of mature differenti-
ated and integrated neurons (NeuN+/BrdU+/cFos+ cells) as
described previously (Kee et al., 2007), with slight modifications.
For these purposes free-floating sections (30 lm thick) were
washed in PBS and incubated for 120 min in blocking solution
(PBS, 0.5% Triton X-100 and containing 5% donkey serum, Serotec,
UK) and then incubated overnight at 4 C in blocking solution with
the following primary antibodies (Ab): rabbit anti Ki-67 (Abcam,
UK); goat anti Doublecortin (Santa Cruz Biotechnology, USA);
mouse anti NeuN (Millipore, UK) and rabbit anti c-Fos (Abcam,
UK). Antigens were visualized by using the following
fluorochrome-conjugated secondary Abs: donkey-anti rabbit,
anti-goat or anti-mouse Alexa Fluor 488 to detect Ki-67, DCX or
NeuN, respectively, and donkey-anti rabbit Alexa Fluor 647 to
detect c-Fos (Invitrogen, UK). Sections used to detect NeuN and
c-Fos were then fixed for 15 min in 4% paraformaldheyde solution,
washed with PBS and then the BrdU detection was started. Sections
were first incubated in HCl 2 N at 37 C for 30 min in order to dena-
ture the DNA chain and, after washing in PBS, were incubated in
blocking solution as described above. BrdU antigen was visualized
by using a sheep-anti-BrdU Ab (Abcam, UK) and an anti-sheep Cy3
as secondary Ab (Millipore, UK). Finally, all sections were washed
with PBS and mounted onto slides and cover slipped with Prolong
anti-fade medium (Life Sciences, Paisley, UK). Controls performed
in parallel without primary antibodies showed very low levels of
nonspecific staining.
2.9. Optical density and cell quantification on confocal images
All images were acquired in a blinded manner by laser-scanning
confocal microscopy (LSM710; Zeiss, Munich, Germany). To ana-
lyze the proliferation of NPCs labeled by Ki67, four images from
five consecutive sections were captured to cover the total exten-
sion of the SVZ per animal, starting at 1.70 mm from bregma untilPlease cite this article in press as: Pradillo, J.M., et al. Reparative effects of inte
cerebral ischemia. Brain Behav. Immun. (2016), http://dx.doi.org/10.1016/j.bbi-0.40 mm (Supp. Fig. 4A; regions A to D). The distance between
image A and B was 200 lm; distance between B-C and C-D was
400 lm, and z-stacks of each image were obtained at 20x.
To study the effect of IL-1Ra on neuroblasts migration (DCX+
cells) we follow the protocol described previously by Moraga
et al., in 2014, where the migration of these cells was studied in
mice after stroke (Moraga et al., 2014). Then, immunofluorescence
z-stack images were obtained at 20 from five correlative sections
of each brain. We established three different zones to analyze the
neuroblast migration, starting at the SVZ (zone 1) and two adjacent
zones (Zone 2 and Zone 3) along the Corpus Callosum (see Fig. 5A).
The analysis of both, the effect of IL-1Ra on Ki67 immunostaining
and DCX+ cells migration images were performed by integrated
density calculations using Volocity 3D image analysis software
(Perkin-Elmer, USA).
For the analysis of the number of new integrated neurons
(BrdU+/NeuN+/c-Fos+ cells), immunofluorescence images were
taken from 4 consecutive sections beginning at 1.60 mm from
bregma until 0.20 mm. The images were taken at 40x, spaced
800 lm from each other to cover the entire top of the cortex below
the stroke, using as boundaries the corpus callosum and the end of
the cortex (see Fig. 6A and Supp. Fig. 4B). A total of 30 images/
ipsilateral- hemisphere/section were obtained, and the quantifica-
tion of the new neurons was made using ZEN 2009 software
(Zeiss). All colocalization images shownwere confirmed by orthog-
onal projection of the z-stack files.2.10. Statistical analysis
Group sizes (n = 6–10) were calculated based on previous data.
Data are presented as mean ± standard deviation (SD). For para-
metric data, Student’s t-test and two-way ANOVA followed by Bon-
ferroni’s correction were used for single and multiple comparisons
respectively. For non-parametric data, Mann-Whitney U test fol-
lowed by Bonferroni’s correction was performed. Non-parametric
data are presented as median distribution (interquartile range).
Linear association between 2 variables was determined by the
Pearson correlation coefficient.3. Results
3.1. IL-1Ra improves long-term stroke outcome
Delayed IL-1Ra administration at 3 and 6 h reperfusion in aged
lean, aged Cp and youngWistar rats induced a significant reduction
in infarct volume at 24 h and 7d of reperfusion, and a significant
reduction in cortex loss at 28d in young Wistar rats. Reductions
in infarct volume at 24 h of reperfusion were 37%, 42% and 40%
in aged lean, aged Cp and young Wistar rats respectively as mea-
sured by T2W MRI (Fig. 1A and B). A reduction in ischemic damage
in IL-1Ra treated animals was also seen at 7d reperfusion in aged
lean, aged Cp and young rats (24%, 46% and 37% of reduction
respectively), although only reached significance in aged Cp and
young Wistar rats (Fig. 1C). A reduction in cortex loss of 56% was
also observed by Nissl staining in the IL-1Ra treated young Wistar
group at 28d reperfusion compared to the corresponding placebo
treated group (Fig. 1D). Edema was also measured and corrected
for at 24 h and 7d reperfusion in all the animals following ischemic
insult and there was no difference between placebo and IL-1Ra in
any experimental group (data not shown).
IgG staining at 7d reperfusion revealed a reduction of 40%, 48%
and 46% in BBB damage in IL-1Ra treated aged lean, aged Cp and
young Wistar animals respectively, versus their placebo-treated
counterparts (Fig. 2A–C). A reduction of 26% was also observed atrleukin-1 receptor antagonist in young and aged/co-morbid rodents after
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Fig. 1. Effect of delayed administration of IL-1Ra/placebo (3 and 6 h of reperfusion) on brain injury. A: representative images of brain lesions in the different experimental
groups. Total infarct volume (mm3) measured at 24 h (B) and 7d (C) after tMCAo in T2W images in aged lean (n = 10), aged Cp (n = 9) and young Wistar rats (n = 8). D: loss of
cortex measured by Nissl staining in young Wistar rats at 28d (n = 8). Data are expressed as mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001, Student’s t-test.
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their placebo counterparts (Supp. Fig. 1).
To assess the impact of delayed IL-1Ra on long term outcome,
motor function and behavior were assessed by different scales
and by the cylinder test, before and at 24 h and 7d following reper-
fusion in all animals, and in additional cohorts of youngWistar rats
at 14d and 28d. Behavioral and motor scores showed all groupsPlease cite this article in press as: Pradillo, J.M., et al. Reparative effects of inte
cerebral ischemia. Brain Behav. Immun. (2016), http://dx.doi.org/10.1016/j.bbiexhibited significant impairment at 24 h compared to baseline.
Aged lean, aged Cp and young Wistar rats treated with IL-1Ra
did however exhibit significantly better performance and smaller
deficits at 24 h and 7d reperfusion versus their control counter-
parts (Fig. 3A–C). Placebo and IL-1Ra treated young Wistar rats
returned to baseline by 28d reperfusion, though IL-1Ra treated ani-
mals had better outcomes versus placebo at 14d (Fig. 3C).rleukin-1 receptor antagonist in young and aged/co-morbid rodents after
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Fig. 2. Effect of delayed administration of IL-1Ra/placebo on BBB damage measured at 7d after tMCAo in aged lean (A; n = 10), aged Cp (B; n = 9) and young Wistar (C; n = 8).
The volume of BBB damage was calculated on brain sections after IgG staining. Data are expressed as mean ± SD. *P < 0.05, **P < 0.01, Student’s t-test. Scale bar: 2 mm.
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the animal rears, revealed no bias of left and right forepaw usage
in any of the groups prior to injury. At 24 h all animals (placebo
or IL-1Ra) displayed deficits in the usage of impaired ipsilateral
and contralateral forepaw, which began to recover by 7d post-
tMCAo (Supp. Fig. 2A–C). IL-1Ra treated lean and young rats
showed improvements in total number of rears versus their pla-
cebo treated counterparts at 24 h and 7d (Supp. Fig. 3A and C).
There were no differences in any groups in the use of ipsilateral
forepaw, contralateral forepaw or both forepaws (data not shown)
at any time point examined (Supp. Fig. 2A–C).
3.2. IL-1Ra increases neurogenesis
Neurogenesis markers were examined by immunofluorescence
at 7d reperfusion in aged leans, aged Cp and young Wistar rats,
and only in the latter at 14d and 28d. We first analyzed prolifer-
ation of NPCs in the SVZ at 7d reperfusion using Ki67, a nuclear
protein associated with cellular proliferation. We identified Ki67Please cite this article in press as: Pradillo, J.M., et al. Reparative effects of inte
cerebral ischemia. Brain Behav. Immun. (2016), http://dx.doi.org/10.1016/j.bbiimmuno-positive cells in the SVZ, indicating the existence of NPCs
proliferation in both placebo and IL-1Ra treated animals. An
increase in the area of NPC proliferation was seen in all animals
treated with IL-1Ra versus placebo-treated, though this was
statistically significant only in aged lean and young Wistar rats
(Fig. 4A and B). In agreement with existing literature (Moraga
et al., 2014, 2015), our results showed a positive but not signifi-
cant correlation between lesion size at 24 h and proliferation of
NPCs at 7d in young Wistar rats (R2 = 0.87, p = 0.06) and no
correlation for aged-comorbid rats (i.e. aged Lean rats: R2 = 0.2,
p = 0.44).
To determine if NPCs have differentiated into immature neu-
rons (neuroblasts) we stained for doublecortin (DCX), a micro-
tubule associated phosphoprotein used as a neuroblast marker,
and analyzed their migration through the corpus callosum towards
the infarcted area. We identified DCX+ neuroblasts in the SVZ (zone
1) that migrated to the infarct (zones 2 and 3) in both placebo and
IL-1Ra treated animals. When compared with placebo treated-
animals IL-1Ra treatment increased the total number of immaturerleukin-1 receptor antagonist in young and aged/co-morbid rodents after
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Fig. 3. Effect of IL-1Ra on behavioral and motor deficits. Behavioral and motor scores were assessed before, 24 h and 7d after tMCAo in aged lean (A; n = 10), aged Cp (B; n = 9)
and in youngWistar animals also at 14 and 28d after cerebral ischemia (C; n = 8). Data are presented as median and interquartile range. *P < 0.05, **P < 0.01, ***P < 0.001, Mann-
Whitney U test with Bonferroni correction.
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infarct, in all groups at 7d of reperfusion (Fig. 5B and C), and in
young animals at 14d (Supp. Fig. 5A and B).
We also studied the number of mature differentiated and inte-
grated neurons (NeuN+/BrdU+/cFos+ cells) in the ipsilesional cortex
of young Wistar rats at 28d after the ischemic insult. Delayed IL-
1Ra treatment resulted in increased numbers of new integrated
neurons compared to the placebo treated animals (Fig. 6B–D),
demonstrating that IL-1Ra not only protects the ischemic brain
but also increases neurogenesis after stroke.
Finally, we analyzed if there was any correlation between the
improvement in functional outcomes seen in the IL-1Ra treated
groups with markers of neurogenesis (NPCs proliferation, DCX
migration and number of new integrated neurons). Our results
showed positive but not significant correlations between thePlease cite this article in press as: Pradillo, J.M., et al. Reparative effects of inte
cerebral ischemia. Brain Behav. Immun. (2016), http://dx.doi.org/10.1016/j.bbibehavioral (positive slopes) and motor (negative slopes) outcomes
and proliferation (Ki67-area of staining) and neuroblast migration
in all the IL-1Ra treated groups and no correlation for the same
outcomes and same neurogenesis markers in the placebo groups
in young Wistar and Lean/Cp rats (data not shown). In contrast,
for young Wistar rats, correlations between behavior score/new
neurons at 28d (positive slope) and the motor score/new neurons
at 28d (negative slope) were positive in the IL-1Ra treated group
up to 14d and only significant in this group up to 7d post-
ischemia, and no correlations in the Placebo youngWistar for these
parameters were observed (24 h behavior score versus new neu-
rons: R2 = 0.9454 and p = 0.02; 7d behavior score versus new neu-
rons: R2 = 0.9 and p = 0.02; 24 h motor score versus new neurons:
R2 = 0.92 and p = 0.04; 7d motor score versus new neurons:
R2 = 0.95 and p = 0.04).rleukin-1 receptor antagonist in young and aged/co-morbid rodents after
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Fig. 4. Effect of IL-1Ra on NPCs proliferation. A: Representative images of Ki67 immunostaining at 7d after tMCAo in aged lean, aged Cp and young Wistar (n = 6). B: Area of
Ki67 immunostaining along the SVZ quantified in 5 consecutive brain sections/brain. Data are expressed as mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001, two-way ANOVA with
Bonferroni correction. Scale bar: 50 lm.
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Our findings demonstrate that subcutaneous administration of
IL-1Ra is neuroprotective in young and aged animals with multiple
risk factors for stroke and increases post-stroke neurogenesis.
It has previously been observed that delayed administration of
IL-1Ra exerts neuroprotective effects at acute time points following
experimental ischemia (Pradillo et al., 2012; Greenhalgh et al.,
2010). Here we extend these findings to show that the early bene-
ficial effects of IL-1Ra persist for at least 7 days in aged/co-morbid
animals and for 28 days in young/healthy animals. It should be
noted that there is significant infarct resorption over time, making
it difficult to directly compare infarct volumes across the different
timepoints. Delayed administration of IL-1Ra resulted in a reduced
infarct volume, a preservation of BBB integrity and improvements
in some functional outcomes.
A meta-analysis of pre-clinical research in cerebral ischemia
showed in 2009 the potential benefit of IL-1Ra (Banwell et al.,
2009) and in a recent cross-lab study performed across Europe,
neuroprotective effects of IL-1Ra in experimental stroke were con-Please cite this article in press as: Pradillo, J.M., et al. Reparative effects of inte
cerebral ischemia. Brain Behav. Immun. (2016), http://dx.doi.org/10.1016/j.bbifirmed (Maysami et al., 2015). Furthermore, IL-1Ra showed some
beneficial effects in a small phase II clinical study in acute stroke
patients (Emsley et al., 2005). Our study confirms the protective
nature of IL-1Ra in co-morbid animals at delayed time points, pro-
viding yet further validation of IL-1Ra as a highly promising ther-
apy for ischemic stroke.
Obesity is commonly associated with increased ischemic dam-
age due to raised levels of pro-inflammatory cytokines and pro-
teases (Sola et al., 2009; McColl et al., 2010). Our data show that
although 13-month-old corpulent rats had a plethora of stroke
associated co-morbidities, infarct volumes were of a similar size
to aged leans, suggesting that the extent of ischemic damage was
close to maximal and that no further increase was possible. Con-
versely, younger rats were more resistant to the distal MCAO and
occlusion time, showing only very small infarcts which necessi-
tated a modification to the surgery protocol (tandem occlusion of
the MCA and CCA) to attain similar infarcts across all strains for
the purpose of examining neurogenesis. This suggests that age is
the primary variable that increases the brain susceptibility to
infarction following an ischemic stroke. However, despite reachingrleukin-1 receptor antagonist in young and aged/co-morbid rodents after
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circumstances if IL-1Ra is administered within a therapeutic
window.
Edema often accompanies brain injury and is acknowledged as
a critical component in the pathology of cerebral ischemia. The
model of ischemia employed might explain the lack of reduction
in edema seen here following IL-1Ra administration. In this model,
a craniectomy is required to allow direct access and manipulation
of the MCA, a procedure that alters intracranial pressure and thus
the volume of edema (Doerfler et al., 1996; Altintas et al., 2015).
Previous studies from our lab have shown significant improve-
ments in edema in rats treated with IL-1Ra who have undergone
transient MCAO using the filament model, a model that does not
involve craniectomy (Girard et al., 2014; Greenhalgh et al., 2010).
To demonstrate that IL-1Ra not only reduces the infarct size but
also improves the functional outcome, we performed in young
Wistar and in aged/comorbid animals two general tests to analyze
motor and behavioral deficits, and the cylinder test to determine
forepaw asymmetry when the animal rears. Although with the first
two tests we have been able to see an improvement in function
with IL-1Ra treatment up to 14d in young animals, modest results
were obtained with the cylinder test, only observing some
improvements in rearing in young Wistar and aged Lean cohorts.
One possible reason for this lack of effect is that the stroke model
used here affects only the sensorimotor cortex and produces smal-Please cite this article in press as: Pradillo, J.M., et al. Reparative effects of inte
cerebral ischemia. Brain Behav. Immun. (2016), http://dx.doi.org/10.1016/j.bbiler infarct volumes when compared to other models (i.e. the fila-
ment model). Despite the modest results obtained in the cylinder
test, our other results demonstrate that IL-1Ra improves the stroke
outcome at longer time points (using the motor and behavioral
scales) and that these improvements in function correlate with
some neurogenesis markers. Beyond the acute phase of ischemic
stroke, gross motor impairments generally resolve rapidly. It is
therefore important to implement fine, long term motor testing
to fully examine differences in genuine recovery and functional
compensation and the effects of drug therapies on discrete motor
deficits, as we have previously done with IL-1Ra (Girard et al.,
2014). As well as motor impairments stroke survivors can experi-
ence a number of other complications, including cognitive decline,
fatigue and depression. Evaluation of the effects of IL-1Ra and
other potential stroke treatments on these parameters would be
worthwhile, though at present the levels of such deficits in exper-
imental stroke models remain poorly characterized.
The capacity of the brain to reorganize and repair itself after
stroke can be seen clinically, even in the case of aged individuals
(Minger et al., 2007). Aging and inflammatory co-morbidities are
generally associated with a decline in general cerebral function,
however the extent to which neurogenesis is affected under such
conditions is unclear. To explore effects of IL-1Ra on markers of
neurogenesis following ischemia it was essential to ensure initial
infarct volumes were consistent across placebo groups, since thererleukin-1 receptor antagonist in young and aged/co-morbid rodents after
.2016.11.013
Fig. 6. Effect of delayed administration of IL-1Ra on the number of new integrated neurons in young Wistar rats at 28d after transient cerebral ischemia (n = 6). A: Brain
template showing the cortical regions of analysis, appearing in grey the region of the peri-infarct where the new neurons were found. B and C: Representative images of the
different experimental groups, where the triple positive cells are shown by white arrows. D: Number of new integrated neurons (NeuN+/BrdU+/c-Fos+ cells) per hemisphere at
28d after tMCAo in placebo or IL-1Ra treated young Wistar rats (n = 6). Data are expressed as mean ± SD. *P < 0.05, Student’s t-test. Scale bar: 25 lm.
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infarct size in rats and mice at 7 days recovery (Moraga et al.,
2014; Abeysinghe et al., 2014). In this study we observe that pro-
liferating NPCs and neuroblasts are preserved in aged animals with
different pre-existing inflammatory conditions, demonstrating the
brain’s potential to repair itself is still viable in aged, co-morbid
strains. Furthermore, our results indicate that although the delayed
administration of IL-1Ra (3 and 6 h from reperfusion onset)
reduces infarct volume, it produces an increase on cellular prolifer-
ation and migration of immature neurons versus placebo counter-
parts in the SVZ following stroke in young and aged/co-morbid
rats, suggesting that a reduced inflammation of the tissue fosters
a more efficient repair of the damaged tissue. We also show that
IL-1Ra increases the number of new integrated neurons in areas
surrounding the infarct lesion in young animals compared to pla-
cebo groups a result that correlates with improvements in motor
and behavioral sub-acute outcomes. The benefits of IL-1Ra are
therefore not limited to inducing neuroprotection, but also favor
and promote neurorepair mechanisms.
Previous studies have examined the beneficial effects of IL-1Ra
on neurogenesis in young healthy animals in models of chronic
stress and Alzheimer’s disease like pathology (Ben Menachem-
Zidon et al., 2008; Ben-Menachem-Zidon et al., 2014). In agree-
ment with this data, the detrimental actions of IL-1b on adult neu-
rogenesis have also been observed in young mice with an IL-1b
excisionally activated transgene which results in chronic expres-
sion of this cytokine (Wu et al., 2012). Despite all these promising
studies, the authors conclude that further studies are required to
fully elucidate the mechanisms through which IL-1Ra may be
mediating its beneficial, neurogenic effects.Please cite this article in press as: Pradillo, J.M., et al. Reparative effects of inte
cerebral ischemia. Brain Behav. Immun. (2016), http://dx.doi.org/10.1016/j.bbiIn conclusion, we demonstrate that IL-1Ra protects against
ischemic brain injury and improves functional recovery in aged/
co-morbid animals when administered peripherally at delayed
time points. Furthermore, IL-1Ra has the potential to improve neu-
rogenesis in these animals, therefore providing a means of enhanc-
ing recovery in patients with a raised inflammatory burden.Competing financial interest
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